These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 7847357)

  • 1. Limitations of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients.
    Bechtel U; Mücke C; Feucht HE; Schiffl H; Sitter T; Held E
    Am J Kidney Dis; 1995 Feb; 25(2):291-6. PubMed ID: 7847357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations.
    Martin KJ; Ballal HS; Domoto DT; Blalock S; Weindel M
    Am J Kidney Dis; 1992 Jun; 19(6):540-5. PubMed ID: 1595702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
    Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS
    Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulse oral calcitriol to treat hyperparathyroidism in 43 CAPD patients.
    Juergensen P; Santacroce S; Mooraki A; Cooper K; Finkelstein FO; Kliger AS
    Adv Perit Dial; 1994; 10():259-60. PubMed ID: 7999840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of oral calcitriol single weekly pulse in CAPD and in HD.
    Romanini D; Gazo A; Bellazzi R; de Vincenzi A; Nai M; Santagostino M
    Adv Perit Dial; 1994; 10():267-9. PubMed ID: 7999842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
    Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
    Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial.
    Herrmann P; Ritz E; Schmidt-Gayk H; Schäfer I; Geyer J; Nonnast-Daniel B; Koch KM; Weber U; Hörl W; Haas-Wörle A
    Nephron; 1994; 67(1):48-53. PubMed ID: 8052367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G; Schmitt CP; Testa S; Claris-Appiani A; Mehls O
    Pediatr Nephrol; 2000 Jul; 14(7):664-8. PubMed ID: 10912539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
    Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
    Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
    Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
    Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
    Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F; Yudd M
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal pulse calcitriol in the treatment of secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
    Chan HW; Tsang WK; Chan CM; Fung SK; So SO; Tang HL; Tong MK; Lee KC; Chan AY
    Perit Dial Int; 1998; 18(2):177-82. PubMed ID: 9576366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
    Hostutler RA; DiBartola SP; Chew DJ; Nagode LA; Schenck PA; Rajala-Schultz PJ; Drost WT
    J Vet Intern Med; 2006; 20(6):1307-13. PubMed ID: 17186842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of marked hyperphosphatemia during intravenous calcitriol therapy in hemodialysis patients with refractory hyperparathyroidism.
    Descombes E; Vogel G; Rosman J; Wauters JP
    Blood Purif; 1996; 14(3):234-41. PubMed ID: 8738537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.